CSV April 4, 2023 through April 4, 2025 All Errata for USP–NF How to use

×

**How to Use**

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| BENDAMUSTI | ADDITIONAL R | *USP42–NF37* | 487 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | In USP |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| NE HYDROCHLORIDE FOR INJECTION | EQUIREMENTS/*USP Reference Standards <11>* | | | | | | | Bendamustine Related Compound B RS: Change 4-(1-Methyl-5-morph olino-1*H* -benzimidazol-2 -yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morph olino-1*H* -benzimidazol-2 -yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot x$ HCl |
| ZINC SULFATE | CHEMICAL INFORMATION | *USP42–NF37* | 4649 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | Change Zinc sulfate (1:1) monohydrate 179.46 to: Zinc sulfate (1:1) monohydrate |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ANAGRELIDE CAPSULES | PERFORMANCE TESTS/ *Dissolution <711>/Analysis* | *USP42–NF37* | 329 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | 179.45 [7446-19-7]. AND Change 287.56 to: 287.54 Change Result = ($r_U/r_S$) x ($C_S/C_U$) x ($M_{r1}/M_{r2}$) x ($V/L$) x 100 to: Result = ($r_U/r_S$) x $C_S$ x ($M_{r1}/M_{r2}$) x ($V/L$) x 100 AND Delete $C_U$ = nominal concentration of anagrelide in the *Sample solution* (mg/mL) |
| HYDROCHLOROTHIAZIDE CAPSULES | PERFORMANCE TESTS/ *Dissolution <711>/Test 2* | *USP42–NF37* | 2171 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | In *Empty capsules solution*: Change Place 10 Capsules to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| PENICILLAMINE CAPSULES | PERFORMANCE TESTS/ *Dissolution <711>* | *Revision Bulletin (Official June 11, 2019)* | Online | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | Place 10 empty capsules<br>In *Procedure for a pooled sample/ Analysis*:<br>Change<br>Result = $(A_U/A_S) \times (C_S/C_U) \times V \times (1/L) \times 100$<br>to:<br>Result = $(A_U/A_S) \times C_S \times V \times (1/L) \times 100$<br>AND<br>Change<br>$C_S$ = concentration of USP Penicillamine RS in the *Standard solution* (µg/mL)<br>to:<br>$C_S$ = concentration of USP Penicillamine RS in the *Standard solution* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | (mg/mL)<br>AND<br>Delete<br>$C_U$ = nominal concentration of penicillamine in the *Sample solution* (µg/mL)<br>AND<br>In *Procedure for a unit sample/ Analysis*:<br>Change<br>Result = $(r_U/r_S)$ × $(C_S/C_U)$ × $V$ × $(1/L)$ × 100<br>to:<br>Result = $(r_U/r_S)$ × $C_S$ × $V$ × $(1/L)$ × 100<br>AND<br>Delete<br>$C_U$ = nominal concentration of in the *Sample solution* (mg/mL)<br>Change<br>(±)-2-Difluoromethyl 1,2,2,2-tetr |
| DESFLURANE | CHEMICAL INFORMATION | *USP42–NF37* | 1230 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | afluoroethyl ether<br>to:<br>(±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether;<br>2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane. |
| ASHWAGANDHA ROOT DRY EXTRACT | COMPOSITION /*Content of Withanolides* | *USP42–NF37* | 4724 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | In the first equation in *Analysis*:<br>Change<br>$C_S$ = concentration of USP Withanoside IV RS in *Standard solution A* (mg/mL)<br>to:<br>$C_S$ = concentration of USP Withanolide A RS in *Standard solution A* (mg/mL) |
| BENDAMUSTINE HYDROCH | IM PUR | *USP42–NF37* | 487 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | In *Table 2*:<br>Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| LORIDE FOR INJECTION | ITIES/*Organic Impurities* | | | | | | | Bendamustine related compound B to: Bendamustine related compound B[a] AND Change Bendamustine related compound C[a] to: Bendamustine related compound C[b] AND Change Bendamustine related compound G[a] to: Bendamustine related compound G[b] AND Change Bendamustine related compound I[a] to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Bendamustine related compound I[b] AND Change [a] This process impurity is controlled in the drug substance monograph. It is included in the table for identification only, and it is not to be reported in the total impurities. to: [a] It is a free base of USP Bendamustine Related Compound B RS: 4-(1-Methyl *H* -benzimidazol-2 -yl)butanoic acid. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | [b] This process impurity is controlled in the drug substance monograph. It is included in the table for identification only, and it is not to be reported in the total impurities. |
| TRIFLUOPERAZINE HYDROCHLORIDE TABLETS | *Assay* | *USP42–NF37* | 4473 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | Change 2(407.51/480.43)$C(r_U/r_S)$ to: 2000(407.51/480.43)$C(r_U/r_S)$ |
| PAROXETINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *First Supplement to USP42–NF37* | 8788 | 27-Sep-2019 | 1-Oct-2019 | *NA* | *NA* | In USP Paroxetine Related Compound G RS: Change 405.46 to: 441.92 |
| FEXOFENADINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP42–NF37* | 1828 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Fexofenadine Related Compound A RS: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.<br>to:<br>2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid;<br>Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. |
| LEVOFLOXACIN | CHEMICAL INFORMATION | *USP42–NF37* | 2552 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | Change Anhydrous [100986-85-41].<br>to:<br>Anhydrous [100986-85-4]. |
| CHLOROQUINE PHOSPHATE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP42–NF37* | 939 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Chloroquine Related Compound G RS: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | $C_{18}H_{26}Cl_3NO \cdot H_2SO_4$<br>to:<br>$C_{18}H_{26}ClN_3O \cdot H_2SO_4$ |
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *Revision Bulletin (Official August 01, 2018)* | Online | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.<br>to:<br>2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid;<br>Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. |
| OLMESARTAN | IM | *Revision* | Online | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In the *Analysis*: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| MEDOXOMIL TABLETS | PUR ITIES/*Organic Impurities* | *Bulletin (Official March 19, 2019)* | | | | | | Change $C_S$ = concentration of in the *Standard solution* (mg/mL) to: $C_S$ = concentration of USP Olmesartan Medoxomil RS in the *Standard solution* (mg/mL) |
| FEXOFENADINE HYDROCHLORIDE CAPSULES | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP42–NF37* | 1830 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 538.12 to: 2-(4-{4-[4-(Hydroxydiphenylmet |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | hyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 499.65 |
| SILDENAFIL CITRATE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP42–NF37* | 4002 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Sildenafil Related Compound A RS: Change 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one. C |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | $^{23}H_{32}N_6O_4S$ 488.60 to: 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one; Also known as 1-{[3-(6,7-Dihydro-1-methyl-7-oxo-3-isobutyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl}-4-methylpiperazine. $C_{23}H_{32}N_6O_4S$ 488.61 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| CIDOFOVIR INJECTION | IM PURITIES/*Organic Impurities* | *USP42–NF37* | 981 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In *Table 1*: Change 0.56 to: 0.59 |
| MECLOFENAMATE SODIUM | CHEMICAL INFORMATION | *USP42–NF37* | 2706 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W. |
| MORPHINE SULFATE EXTENDED-RELEASE CAPSULES | IM PURITIES/*Organic Impurities* | *USP42–NF37* | Online | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | Change *Diluent*, *Solution A*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Proceed as directed in the *Assay*.<br>to:<br>*Diluent*, *Buffer solution*, *Solution A*, *Solution B*, *Mobile phase*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*. |
| CALCIUM CARBONATE | IM PURITIES/*Limit of Magnesium and Alkali Salts* | *USP42–NF37* | 666 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | Change *Sample solution*: 1.0 g<br>to:<br>*Sample*: 1.0 g |
| FEXOFENADINE HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *Revision Bulletin (Official November 01, 2018)* | Online | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4- |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | [4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.<br>to:<br>2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid;<br>Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. |
| PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE | 19. MEAN KINETIC TEMPERATURE | *USP42–NF37* | 7831 | 30-Aug-2019 | 1-Sep-2019 | *NA* | *NA* | In *19.4 Example Calculations of MKT for CRT Storage Evaluation/Example 3—Calculation of Annual MKTStep 3*:<br>Change<br>3.354<br>to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | 3.340<br>AND<br>In *Step 4*:<br>Change<br>2.795<br>to:<br>2.783<br>AND<br>In *Step 5*:<br>Change<br>?33.511<br>to:<br>?33.515<br>AND<br>In *Step 6*:<br>Change<br>298.410<br>to:<br>298.372 |
| G49 | CHROMATOGRAPHIC COLUMNS/*Packings* | *First Supplement to USP40–NF35* | 8127 | 28-Jul-2019 | 20-Apr-2019 | *USP42–NF37* | *First Supplement to USP41–NF36* | Add G49—Dimethylpolysiloxane with chiral building block containing D- or L-valine as chiral agent (for amino acids). |
| TIAGABINE HYDROCHLORIDE | IMPURITIES/*Limit of (S)-(+)* | *First Supplement to USP42–NF37* | 8823 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change<br>Hexane,<br>to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Isomer/Mobile phase* | | | | | | | *n*-Hexane, AND Change hexane to: *n*-hexane |
| BUSPIRONE HYDROCHLORIDE TABLETS | IDENTIFICATION/*B.* | *USP42–NF37* | 621 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change relative retention time to: retention time |
| GLUCAGON BIOIDENTITY TESTS | *B. In Vitro Cell-Based Bioidentity Test* | *USP42–NF37* | 6478 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Standard stock solution*: Change 0.4 µg/mL to: 4 µg/mL |
| OXALIPLATIN INJECTION | IM PURITIES/*Limit of Oxalic Acid/ Chromatographic system* | *First Supplement to USP42–NF37* | 8781 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Column*: Change L31 to: L81 |
| ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION | SPECIFIC TESTS/ *Microbial Enumeration Tests <61> and Tests for Specified Microorganisms* | *USP42–NF37* | 170 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change cfu/g to: cfu/mL |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *<62>* | | | | | | | |
| VALGANCICLOVIR HYDROCHLORIDE | *Related compounds* | *USP42–NF37* | 4528 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In Column 2 of *Table 3*:<br>Change<br>Bis-valine easter of ganciclovir<br>to:<br>Bis-valine ester of ganciclovir |
| LAMOTRIGINE TABLETS FOR ORAL SUSPENSION | PERFORMANCE TESTS/ *Dissolution <711>/ Chromatographic procedure 1* | *First Supplement to USP42–NF37* | 8720 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Buffer*:<br>Change<br>glacial acetic acid acid<br>to:<br>glacial acetic acid |
| BALANCES | REPEATABILITY | *First Supplement to USP42–NF37* | 9011 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In all instances in paragraph 2:<br>Change<br>$s_r$<br>to:<br>$s$<br>AND<br>In paragraph 2:<br>Change<br>is found to be 0.0015, then $M_{min}$ must be ? 0.3000 g or 300 mg. |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to:<br>is found to be 0.00015, then $M_{min}$ must be ? 0.30000 g or 300.00 mg. |
| CHLOROTHIAZIDE | *Selenium <291>* | *USP42–NF37* | 942 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change 0.003%.<br>to:<br>NMT 0.003%. |
| BENAZEPRIL HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/ *Dissolution <711>/Test 1* | *First Supplement to USP42–NF37* | 8644 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In the *Standard solution*:<br>Change µg/mL<br>to:<br>µg/µL |
| TIAGABINE HYDROCHLORIDE | ASSAY/ *Procedure* | *First Supplement to USP42–NF37* | 8823 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Analysis*:<br>Change Result = $(R_U/R_S) \times (C_S/C_U) \times$ ?$(M_{r1}/M_{r2}) \times$? (USP 1-Aug-2019) 100<br>to:<br>Result = $(R_U/R_S) \times (C_S/C_U) \times 100$<br>AND<br>Delete ?$M_{r1}$ = molecular |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | weight of tiagabine hydrochloride, 412.00<br>$M_{r2}$ = molecular weight of tiagabine hydrochloride monohydrate, 430.02? (USP 1-Aug-2019) |
| BUSPIRONE HYDROCHLORIDE | IDENTIFICATION/*B.* | *USP42–NF37* | 618 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change relative retention time to: retention time |
| POWDERED MILK THISTLE EXTRACT | COMPOSITION/*Content of Silymarin* | *USP42–NF37* | 5102 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Table 2*: Change Tsosilybin B to: Isosilybin B |
| LOVASTATIN TABLETS | PERFORMANCE TESTS/*Dissolution <711>* | *First Supplement to USP42–NF37* | 8727 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *Mobile phase*: Change Processed as directed in the *Assay* to: Proceed as directed in the *Assay*. |
| ALPROSTADIL | ASSAY/ | *USP42–NF37* | 151 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | In *System* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Procedure* | | | | | | | *suitability stock solution*: Change *Standard solution* to: *Standard stock solution* |
| IOVERSOL | CHEMICAL INFORMATION | *USP42–NF37* | 2345 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Change *N*,*N* ?-Bis(2,3-dihydrox ypro pyl)-5-*N* -(2-hydroxyethyl )glycol amido]-2 ,4,6-triiodoisoph thalamide. to: *N*,*N* ’-Bis(2,3-dihydrox ypro pyl)-5-[*N* -(2-hydroxyethyl )glycolamido]-2, 4,6-triiodoisopht halamide. |
| EPHEDRINE HYDROCHLORIDE | CHEMICAL INFORMATION | *First Supplement to USP42–NF37* | 8682 | 26-Jul-2019 | 1-Aug-2019 | *NA* | *NA* | Add (1*R*,2*S* )-2-(Methylamin |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | o)-1-phenylpropan-1-ol hydrochloride; |
| ETIDRONATE DISODIUM | SPECIFIC TESTS/*Water Determination <921>* | *USP42–NF37* | 1745 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *Sample solution*: Change acetic acid to: glacial acetic acid |
| CHOLINE BITARTRATE | IM PURITIES/*Limit of Total Amines*/*System suitability* | *USP42–NF37* | 4839 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *Suitability requirements*: Change ?g/L. to: ?g/mL. |
| ACETAMINOPHEN ORAL SUSPENSION | ASSAY | *Second Supplement to USP41–NF36* | Online | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In the first *Procedure*: Change ?(Postponed on 1-Aug-2018) to: |
| VORICONAZOLE | IM PUR | *USP42–NF37* | 4601 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | ?(RB 1-Aug-2018) In *System suitability* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | ITIES/ *Voriconazole Related Compounds C and D* | | | | | | | *solution*: Change 0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in *Mobile phase* |
| SAW PALMETTO CAPSULES | IDENTIFICATION/*B. Presence of Sterols* | *USP42–NF37* | 5198 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS, and 0.37 mg/mL of stigmastanol to: 0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?- |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| POLYVINYL ALCOHOL | IDENTIFICATION | *USP42–NF37* | 3566 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | Sitosterol RS in chloroform<br>In *B*: Change<br>It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, and *Viscosity—Rolling Ball Method <913>*.<br>to:<br>It meets the requirements in the test *Viscosity—Capillary Methods <911>*, *Viscosity—Rotational Methods <912>*, or *Viscosity—Rolling Ball Method <913>*. |
| CHOLINE CHLORIDE | IM PURITIES/*Limit of Total* | *USP42–NF37* | 4841 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *Suitability requirements*: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | *Amines*/*System suitability* | | | | | | | ?g/L.<br>to:<br>?g/mL. |
| MORPHINE SULFATE EXTENDED-RELEASE CAPSULES | PERFORMANCE TESTS/ *Dissolution <711>* | *Revision Bulletin (Official November 01, 2018)* | Online | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *Test 1*/*Tolerances* and *Test 3*/*Tolerances*:<br>Change<br>$[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O)]$<br>to:<br>$[(C_{17}H_{19}NO_3)_2 \cdot H_2SO_4 \cdot 5H_2O]$ |
| ZONISAMIDE | IMPURITIES/*Organic Impurities* | *USP42–NF37* | 4675 | 28-Jun-2019 | 1-Jul-2019 | *NA* | *NA* | In *Analysis*:<br>Change<br>$C_U$ = concentration of zonisamide related compound A in the *Sample solution* (mg/mL)<br>to:<br>$C_U$ = concentration of zonisamide in the *Sample solution* (mg/mL) |

**Pagination**

- First page « First
- Previous page ‹ Previous
- …
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- …
- Next page Next ›
- Last page Last »